GLP-1 Receptor Agonist for Reduction of Myocardial Injury After Non-cardiac Surgery
- Status
- RecruitingResults none
- Why it is watched
- non-weight indication: cardiovascular
- Who it enrolls
- age 18 Years to no upper limit; no BMI minimum stated; conditions: Myocardial Injury
- Interventions
- Dulaglutide 0.75mg subcutaneous injection
- Conditions
- Myocardial Injury
- Phase and size
- Phase 4 · 372 participants
- Dates
- Start 2024-03-20
Primary completion 2028-12-31 - Sponsor
- The University of Hong Kong (Other)
- Last checked
- Sep 13, 2026
01Endpoints
What the trial will measure
- Proportion of patients with MINSWithin 72 hours after surgery
02Eligibility
Who can take part
Inclusion Criteria: * Age ≥ 18 years * Planned elective intermediate to high risk non-cardiac surgery * Anticipated to remain hospitalized for at least one night after surgery * Voluntarily agrees to participate by providing written informed consent Exclusion Criteria: * History of symptomatic hypoglycemia within 1 month of recruitment * History of pancreatitis * Diabetic retinopathy * Personal or family history of medullary thyroid carcinoma (MTC) * Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) * Acute coronary syndrome, decompensated heart failure, cardiogenic shock, or myocarditis within 1 month of recruitment * Stroke or transient ischemic attack within 1 month of recruitment * Known severe liver disease (Child-Pugh B or C) * Stage 5 chronic kidney disease (estimated glomerular filtration rate (eGFR) by Modified Diet in Renal Disease (MDRD) equation \< 15 mL/min) * Recent use of GLP-1 RA within 1 month of recruitment * Known allergy or hypersensitivity to GLP-1 RA * Women of childbearing age who are not taking effective contraception, or who are pregnant or breast-feeding * Use of Dipeptidyl peptidase-4 inhibitor(DPP4i)
03Change log
Registry changes
No changes recorded since the trial was added.